Friday, August 29, 2025
HomeIndustries

Industries

Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced the initiation of patient dosing in TWT-203, its Phase...

Hollister Incorporated Receives Vizient Contract for Urological Products

Hollister Incorporated, a global medical device company, has been awarded a three-year group purchasing agreement for Urological products with vizient, Inc., the nation's largest...

Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

Biotech Acquisition Company, a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based...

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO

BioMarin Pharmaceutical Inc. presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of...

Zynex Announces Change of Auditor

Zynex, Inc. ("Zynex or the "Company), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management,...
0FansLike
0FollowersFollow
spot_img

Hot Topics